<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The phase III CONFIRM clinical trials demonstrated that <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> patients with elevated serum <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (LDH) had improved outcome when the vascular endothelial growth factor receptor (VEGFR) inhibitor PTK/ZK (Vatalanib) was added to FOLFOX4 chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the hypothesis that high intratumoral expression of genes regulated by <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1 alpha (HIF1α), namely LDHA, <z:chebi fb="105" ids="17234">glucose</z:chebi> transporter-1 (GLUT-1), VEGFA, VEGFR1, and VEGFR2, were predictive of outcome in CONFIRM-1 </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> tissue was isolated by laser-capture microdissection from 85 CONFIRM-1 tumor specimens; FOLFOX4/placebo n=42, FOLFOX4/PTK/ZK n=43 </plain></SENT>
<SENT sid="3" pm="."><plain>Gene expression was analyzed using quantitative RT-PCR </plain></SENT>
<SENT sid="4" pm="."><plain>In univariate analyses, elevated <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of LDHA, GLUT-1, and VEGFR1 were associated with response to FOLFOX4/PTK/ZK </plain></SENT>
<SENT sid="5" pm="."><plain>In univariate and multivariate analyses, elevated LDHA and VEGFR1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels were associated with improved progression-free survival in FOLFOX4/PTK/ZK patients </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, increased HIF1α and VEGFR2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels were associated with decreased survival in FOLFOX/placebo patients but not in patients who received FOLFOX4/PTK/ZK </plain></SENT>
<SENT sid="7" pm="."><plain>These are the first data suggesting intratumoral <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of genes involved in <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>/HIF pathway may predict outcome to VEGFR-inhibitors </plain></SENT>
<SENT sid="8" pm="."><plain>Biomarkers that assist in directing VEGFR-inhibitors toward patients with an increased likelihood of benefit will improve the cost-effectiveness of these promising agents.The Pharmacogenomics Journal advance online publication, 5 June 2012; doi:10.1038/tpj.2012.23 </plain></SENT>
</text></document>